Trials / Completed
CompletedNCT03690362
VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Venatorx Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
This is a multi-center, open-label, PK and safety study of VNRX-5133 and VNRX-5022 when co-administered in male and female subjects with varying levels of renal impairment and healthy normal controls.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VNRX-5133 and VNRX-5022 | intravenous infusion |
Timeline
- Start date
- 2018-04-06
- Primary completion
- 2018-11-21
- Completion
- 2018-11-21
- First posted
- 2018-10-01
- Last updated
- 2019-02-08
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03690362. Inclusion in this directory is not an endorsement.